Explanipedia

Real-World Clinical Outcomes With Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer Open

Sabah Alaklabi, Arya Mariam Roy, Paola Zagami, Anumita Chakraborty, Nicole Held , et al. · 2024

PURPOSE Sacituzumab govitecan (SG) is approved for the treatment of metastatic triple-negative breast cancer (mTNBC). We report the real-world clinical effectiveness and toxicity data of SG in patients with mTNBC. METHODS A multi-instituti…

Immune Cell Molecular Pharmacodynamics of Lanreotide in Relation to Treatment Response in Patients with Gastroenteropancreatic Neuroendocrine Tumors Open

Sabah Alaklabi, Orla Maguire, Harsha Pattnaik, Yali Zhang, Jacky Chow , et al. · 2024

The CLARINET trial led to the approval of lanreotide for the treatment of patients with gastroenteropancreatic neuroendocrine tumors (NETs). It is hypothesized that lanreotide regulates proliferation, hormone synthesis, and other cellular …

Predictors of Complete Pathological Response with Chemoimmunotherapy in Triple-Negative Breast Cancer: A Meta-Analysis Open

Arya Mariam Roy, Supritha Chintamaneni, Sabah Alaklabi, Hassan Awada, Kristopher Attwood , et al. · 2023

Background: Multiple randomized controlled trials (RCTs) have investigated the impact of adding checkpoint inhibitors to neoadjuvant chemotherapy for triple-negative breast cancer (TNBC) patients. However, there is a lack of biomarkers tha…

Facing the conundrum: which first-line therapy should be used for patients with metastatic triple-negative breast cancer carrying germline BRCA mutation? Open

Sabah Alaklabi, Arya Mariam Roy, Lubna N. Chaudhary, Shipra Gandhi · 2023

Pembrolizumab combined with chemotherapy has been established as the preferred first-line therapy for treating metastatic triple-negative breast cancer (mTNBC) with programmed cell death ligand-1 (PD-L1)-positive disease since its approval…

Effect of neighborhood deprivation index on breast cancer survival in the United States Open

Arya Mariam Roy, Anthony George, Kristopher Attwood, Sabah Alaklabi, Archit Patel , et al. · 2023

Effect of Neighborhood Deprivation Index on Breast Cancer Survival in the United States Open

Arya Mariam Roy, Anthony George, Kristopher Attwood, Sabah Alaklabi, Archit Patel , et al. · 2023

Purpose To analyze the association between the Neighborhood Deprivation Index (NDI) and clinical outcomes of early-stage breast cancer (BC). Methods Surveillance, Epidemiology and End Results (SEER) database is queried to evaluate overall …

Immunotherapy in malignant peritoneal mesothelioma (Review) Open

Sabah Alaklabi, Arya Mariam Roy, Joseph J. Skitzki, Renuka Iyer · 2023

Over the last decade, there has been a movement in cancer treatment away from cytotoxic therapies toward strategies that enhance the immune system against cancer. Immune checkpoint inhibitors (ICIs) have been incorporated into the treatmen…

Real world outcomes with alpelisib in metastatic hormone receptor-positive breast cancer patients: A single institution experience Open

Sabah Alaklabi, Arya Mariam Roy, Kristopher Attwood, Anthony George, Tracey L. O’Connor , et al. · 2022

Background It is critically important to study the real-world data of FDA-approved medications to understand the response rates and toxicities observed in the real-world population not represented in the clinical trials. Methods We reviewe…

The prevalence of diverticular disease in the National Guard Health Affairs, Riyadh, Saudi Arabia Open

N Al-Alem, Sabah Alaklabi, M Sadee, K Al-Amer, Muhammad Ahad Sher Khan · 2015

Introduction: Diverticulosis is an outward protrusion of the mucosa and submucosa of the colon. Only 5% of patients may develop inflammation of the diverticula (diverticulitis). Lifestyle and eating habits significantly impact the distribu…

Sabah Alaklabi YOU? Author Swipe